INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4
07/28/2021 - 04:05 PM
Management to host conference call at 4:30 pm E T on that day
BOCA RATON, Florida, July 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Wednesday, August 4, 2021 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2021 and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching an operator.
Date: August 4, 2021
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through August 11 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13721921.
About INmune Bio, Inc.
INmune Bio, Inc www.inmunebio.com
INmune Bio Contact: DMoss@INmuneBio.com
Investor Contact: Chuck@lifesciadvisors.com
INMB Rankings
#2639 Ranked by Stock Gains
INMB Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Medical Specialties, Biotechnology, Health Technology
About INMB
inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.
